RBC Capital Reiterates Outperform Rating on Johnson & Johnson (JNJ)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/9/2026
Go back to RBC Capital Reiterates Outperform Rating on Johnson & Johnson (JNJ)
July 17, 2024 6:25 AM EDT
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--
Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has declared a cash dividend for the third quarter of 2024 of $1.24 per share on the companys common stock. The dividend is payable on September 10,... More
July 17, 2024 6:20 AM EDT
2024 Second-Quarter reported sales growth of 4.3% to $22.4 Billion with operational growth of 6.6%* and adjusted operational growth of 6.5%*. Adjusted operational growth excluding COVID-19 Vaccine of 7.1%*
2024 Second-Quarter Earnings per share (EPS) of $1.93 decreasing by 5.9% due to one-time special charges and adjusted EPS of $2.82 increasing by 10.2%*
Significant new product pipeline progress including TREMFYA IBD and subcutaneous filings, RYBREVANT subcutaneous filing, and VARIPULSE admIRE data release
Company increases Full-Year 2024 operational sales5 guidance to reflect the acquisition of Shockwave Medical
Company updates Full-Year 2024 adjusted operational EPS guidance to reflect improved performance; costs associated... More
